Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Pediatrix Medical Group, Inc.
MD
NYSE·Healthcare·Medical - Care Facilities·Mkt cap $2.1B
$26.55
▲ +1.57%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$11.84 - $26.88
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 89.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Largest network of pediatric subspecialists in the U.S. with ~2,700 physicians
- Integrated care model combining physicians, nurse practitioners, and support clinicians
- Deep hospital relationships and embedded presence in critical care units
- Specialized expertise in high-acuity, complex pediatric conditions
- Multi-state geographic diversification with Puerto Rico presence
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Increasing demand for specialized neonatal and maternal-fetal care services
Value
Undervalued - trading well below Healthcare Facilities peers
Momentum
Hot
+23.4% over 3m
Quality
Stable
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 5, 2026
Reported EPS of $0.44 vs $0.37 consensus (+18.9% surprise). Revenue of $476.2M vs $465.8M expected (+2.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+18.9%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
+1%
-7%
-7%
-4%
-2%
+4%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$504.3M
$511.2M
$502.4M
$458.4M
$468.8M
$492.9M
$493.8M
$476.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
6.2%
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
$25.00
▼ -5.8% vs $26.55
Latest: UBS · $25.00 · May 12, 2026
3 analysts covering